Nuwellis Reports 14% Q2 Revenue Jump, Defying Distress
NUWE is trading near its 52-week low of $1.95 (2.1% above the low).
Summary
Nuwellis posted a 14% year-over-year revenue increase for Q2 2026, with first-half revenue up 20%, indicating double-digit growth. The company recently executed a 1-for-35 reverse split and closed a deeply discounted $6M offering, with shareholders rejecting a warrant share issuance proposal just days ago. This revenue growth suggests some operational traction, but the nano-cap firm still faces a going concern warning and extreme dilution risk. The market will watch whether this top-line improvement can translate into reduced cash burn when full Q2 results are released.
At the time of this announcement, NUWE was trading at $1.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $746.8K. The 52-week trading range was $1.95 to $481.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.